Human papillomaviruses and cancer
Human papillomaviruses and cancer
复制标题
DOI：
10.1016/j.radonc.2013.06.004
复制
发表时间：
2013-09-01
影响因子：
5.7
通讯作者：
Iftner, Thomas
中科院分区：
文献类型：
--
作者：
Haedicke, Juliane;Iftner, Thomas
人乳头瘤病毒(HPV)是一种小的致癌DNA病毒，迄今已鉴定出200多种类型。其中一小部分在病因学上与宫颈癌等肛门生殖系统恶性肿瘤的发展有关。此外，最近的研究确定了这些高危HPV类型与扁桃体和口咽癌之间的因果关系。宫颈癌和头颈部鳞状细胞癌(HNSCCs)的临床治疗在很大程度上是标准化的，包括手术切除肿瘤组织和辅助放化疗。值得注意的是，与HPV阴性的肿瘤相比，HPV阳性的HNSCC对治疗干预的反应更好。虽然现有的HPV疫苗仅被批准用于预防宫颈癌，但它也可能具有预防HPV相关高危HNSCC的潜力。另一组病毒属于β-HPV亚组，已被认为与非黑色素瘤皮肤癌有关，然而，病因仍有待确定。HPV诱导的非黑色素瘤皮肤癌的治疗是基于局部切除。然而，局部应用免疫调节物质是治疗较小皮肤肿瘤的非手术替代方案。在这篇综述中，我们介绍了目前关于HPV在癌症发展中的作用的知识，并讨论了临床治疗选择以及未来介入治疗的发展目标。(C)2013爱思唯尔爱尔兰有限公司。保留所有权利。放射治疗与肿瘤学108(2013)397-402
Human papillomaviruses (HPV) are small oncogenic DNA viruses of which more than 200 types have been identified to date. A small subset of these is etiologically linked to the development of anogenital malignancies such as cervical cancer. In addition, recent studies established a causative relationship between these high-risk HPV types and tonsillar and oropharyngeal cancer. Clinical management of cervical cancer and head and neck squamous cell carcinomas (HNSCCs) is largely standardized and involves surgical removal of the tumor tissue as well as adjuvant chemoradiation therapy. Notably, the response to therapeutic intervention of HPV-positive HNSCCs has been found to be better as compared to HPV-negative tumors. Although the existing HPV vaccine is solely licensed for the prevention of cervical cancer, it might also have prophylactic potential for the development of high-risk HPV-associated HNSCCs. Another group of viruses, which belongs to the beta-HPV subgroup, has been implicated in nonmelanoma skin cancer, however, the etiology remains to be established. Treatment of HPV-induced nonmelanoma skin cancer is based on local excision. However, topically applied immune-modulating substances represent non-surgical alternatives for the management of smaller cutaneous tumors. In this review we present the current knowledge of the role of HPV in cancer development and discuss clinical management options as well as targets for the development of future intervention therapies. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 397-402